英夫利西单抗与依那西普原研药和生物类似药在脊柱关节炎初治患者中的治疗留存比较
这项北欧五国多中心观察性研究纳入2334例首次使用生物制剂的脊柱关节炎患者,其中英夫利西单抗1319例、依那西普1015例,比较原研药与生物类似药的治疗留存。结果显示两组基线特征大体相似,生存概率曲线和留存率高度接近,风险比无统计学意义,提示两类药物在真实临床实践中的有效性相当。
要点
- 脊柱关节炎初治患者中,英夫利西单抗和依那西普的原研药与生物类似药治疗留存高度相似。
- 英夫利西单抗2年留存率原研药44%、生物类似药46%;依那西普1年留存率原研药66%、生物类似药73%。
- 风险比无统计学意义,支持生物类似药在真实临床实践中与原研药有效性相当。
核心结论
- 在脊柱关节炎初治患者中,英夫利西单抗和依那西普的原研药与对应生物类似药的基线特征、生存概率曲线和留存率高度相似,风险比无统计学意义,提示临床实践中有效性相当。
研究设计与样本
- 北欧五国生物制剂风湿病登记研究,纳入2014年1月至2017年6月首次使用英夫利西单抗或依那西普的脊柱关节炎患者,按国家汇总数据,英夫利西单抗与依那西普分别分析。
- 共纳入2334例生物制剂初治脊柱关节炎患者:英夫利西单抗1319例(原研药24%、生物类似药76%),依那西普1015例(原研药49%、生物类似药51%)。
主要发现
- 原研药与对应生物类似药治疗患者的基线特征大体相似。
- 生存概率曲线在原研药与其生物类似药之间高度相似。
- 英夫利西单抗2年留存率:原研药44%(95%CI 38%至50%),生物类似药46%(95%CI 42%至51%)。
- 依那西普1年留存率:原研药66%(95%CI 61%至70%),生物类似药73%(95%CI 68%至78%)。
- 风险比无统计学意义。
关键数值与推荐
- 英夫利西单抗2年留存率原研药44%(95%CI 38%至50%)对比生物类似药46%(95%CI 42%至51%)。
- 依那西普1年留存率原研药66%(95%CI 61%至70%)对比生物类似药73%(95%CI 68%至78%)。
临床怎么用
- 结果支持在脊柱关节炎初治患者中选用英夫利西单抗或依那西普的生物类似药,其真实世界治疗留存与原研药相当。
局限性
- 为观察性研究,非随机对照设计;原文摘要未进一步说明其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare treatment retention in biologics-naïve patients with SpA starting either the originator product or a biosimilar of infliximab and etanercept, and to explore the baseline characteristics of these patients. METHODS: Patients with SpA (ankylosing spondylitis/non-radiographical axial SpA/undifferentiated SpA), starting infliximab or etanercept as their first-ever biological disease-modifying antirheumatic drug during January 2014-June 2017 were identified in five Nordic biologics-rheumatology registers. Baseline characteristics were retrieved from each registry; comorbidity data were identified through linkage to national health registers. Country-specific data were pooled, and data on infliximab and etanercept were analysed separately. Comparisons of treatment retention between originators and biosimilars were assessed through survival probability curves, retention rates (2 years for infliximab/1 year for etanercept) and Hazard Ratios (HR). RESULTS: We included 1319 patients starting infliximab (24% originator/76% biosimilar), and 1015 patients starting etanercept (49% originator/51% biosimilar). Baseline characteristics were largely similar for the patients treated with the originators compared with the corresponding biosimilars. Survival probability curves were highly similar for the originator and its biosimilar, as were retention rates: infliximab 2-year retention originator, 44% (95% CI 38% to 50%)/biosimilar, 46% (95% CI: 42% to 51%); and etanercept 1-year retention originator, 66% (95% CI 61% to 70%)/biosimilar, 73% (95% CI 68% to 78%). HRs were not statistically significant. CONCLUSION: This observational study of biologics-naïve patients with SpA from five Nordic countries showed similar baseline characteristics and very similar retention rates in patients treated with originators versus biosimilars, for both infliximab and etanercept, indicating comparable effectiveness in clinical practice.
引用
- Lindström U, Glintborg B, Di Giuseppe D, et al. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. RMD Open. 2019. PMID: 31749988. doi:10.1136/rmdopen-2019-001079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。